MIAMI--(BUSINESS WIRE)--StemSynergy Therapeutics Inc. is pleased to announce that it has been selected to participate in the NIH SBIR/STTR Innovation zone at the 2014 BIO International Biotechnology Conference. This is an exciting opportunity for SSTI to showcase our drug discovery platform and lead compounds targeting the WNT pathway.
“The Innovation Zone offers an inside look at some of America’s most promising biomedical technology firms strategically positioned and ready for investor and partnering engagement,” said Lenka Fedorkova, PhD, program manager for NIH SBIR/STTR programs. “We are committed to supporting our companies along their path to commercialization and are excited to partner with BIO to showcase the next generation of health care market solutions at BIO’s Innovation Zone.”
StemSynergy Therapeutics is a biopharmaceutical company focused on the discovery and development of novel small-molecule drugs that target developmental pathways fundamental to cancer. Our mission is to optimize efficacy against developmental pathways that drive cancer stem cells, such as the WNT, Sonic Hedgehog and Notch signaling pathways.